Evidence map›Paper›PMID 34537073›Full record

ArticleJournal of experimental & clinical cancer research : CR2021

ZNF507 affects TGF-β signaling via TGFBR1 and MAP3K8 activation in the progression of prostate cancer to an aggressive state.

Wookbong Kwon, Seong-Kyoon Choi, Daehwan Kim, Hyeon-Gyeom Kim, Jin-Kyu Park, Jee Eun Han, Gil-Jae Cho, Sungho Yun, Wookyung Yu, Se-Hyeon Han and 8 more

Open access · goldAbstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Epigenetic Regulation of MAP3K8 in EBV-Associated Gastric Carcinoma.International journal of molecular sciences · 2023
    Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 4 institutions in 1 country.

Wookbong Kwon *Core Protein Resources Center, DGIST, Daegu, Republic of Korea.
Seong-Kyoon Choi *Core Protein Resources Center, DGIST, Daegu, Republic of Korea. cskbest@dgist.ac.kr.ORCID http://orcid.org/0000-0002-0233-4114
Daehwan KimCore Protein Resources Center, DGIST, Daegu, Republic of Korea.
Hyeon-Gyeom KimCore Protein Resources Center, DGIST, Daegu, Republic of Korea.
Jin-Kyu ParkCollege of Veterinary Medicine, Kyungpook National University, 41566, Daegu, Korea.
Jee Eun HanCollege of Veterinary Medicine, Kyungpook National University, 41566, Daegu, Korea.
Gil-Jae ChoCollege of Veterinary Medicine, Kyungpook National University, 41566, Daegu, Korea.
Sungho YunCollege of Veterinary Medicine, Kyungpook National University, 41566, Daegu, Korea.
Wookyung YuDepartment of Brain and Cognitive Sciences, DGIST, Daegu, Republic of Korea.
Se-Hyeon HanSchool of Media Communication, Hanyang University, Wangsimni-ro 222, Seongdong- gu, Seoul, South Korea.
Yun-Sok HaDepartment of Urology, School of Medicine, Kyungpook National University, Daegu, Korea.
Jun Nyung LeeDepartment of Urology, School of Medicine, Kyungpook National University, Daegu, Korea.
Tae Gyun KwonDepartment of Urology, School of Medicine, Kyungpook National University, Daegu, Korea.
Dong-Hyung ChoSchool of Life Science, BK21 FOUR KNU Creative Bioresearch, Kyungpook National University, Daegu, Korea.
Jun-Koo YiGyeongsangbuk-do Livestock Research institute, Yeongju, South Korea.
Myoung Ok KimDepartment of Animal Science and Biotechnology, ITRD, Kyungpook National University, 37224, Sangju, Republic of Korea.
Zae Young RyooSchool of Life Science, BK21 FOUR KNU Creative Bioresearch, Kyungpook National University, Daegu, Korea. jaewoong64@knu.ac.kr.
Song ParkCore Protein Resources Center, DGIST, Daegu, Republic of Korea. cristaling@dgist.ac.kr.
Kyungpook National University · KRDaegu Gyeongbuk Institute of Science and Technology · KRGyeongsangnam-do Agricultural Research and Extension Services · KRKorea Educational Broadcasting System · KR

Funding

Ministry of Science, ICT and Future Planning DGIST 20-CoE-BT-01National Research Foundation of Korea 2020R1A4A1018280
6 · The paper itself

Abstract

backgroundThe progression of prostate cancer (PC) to the highly aggressive metastatic castration-resistant prostate cancer (mCRPC) or neuroendocrine prostate cancer (NEPC) is a fatal condition and the underlying molecular mechanisms are poorly understood. Here, we identified the novel transcriptional factor ZNF507 as a key mediator in the progression of PC to an aggressive state.

methodsWe analyzed ZNF507 expression in the data from various human PC database and high-grade PC patient samples. By establishment of ZNF507 knockdown and overexpression human PC cell lines, we assessed in vitro PC phenotype changes including cell proliferation, survival, migration and invasion. By performing microarray with ZNF507 knockdown PC cells, we profiled the gene clusters affected by ZNF507 knockdown. Moreover, ZNF507 regulated key signal was evaluated by dual-luciferase reporter and chromatin immunoprecipitation (ChIP) assays. Finally, we performed xenograft and in vivo metastasis assay to confirm the effect of ZNF507 knockdown in PC cells.

resultsWe found that ZNF507 expression was increased, particularly in the highly graded PC. ZNF507 was also found to be associated with metastatic PC of a high grade. Loss- or gain-of-function-based analysis revealed that ZNF507 promotes the growth, survival, proliferation, and metastatic properties of PC (e.g., epithelial-mesenchymal transition) by upregulating TGF-β signaling. Profiling of gene clusters affected by ZNF507 knockdown revealed that ZNF507 positively regulated the transcription of TGFBR1, MAP3K8, and FURIN, which in turn promoted the progression of PC to highly metastatic and aggressive state.

conclusionsOur findings suggest that ZNF507 is a novel key regulator of TGF-β signaling in the progression of malignant PC and could be a promising target for studying the development of advanced metastatic PCs.

Indexed as

Signal TransductionAnimalsApoptosisBiomarkersCell Line, TumorCell MovementCell ProliferationDisease ProgressionDisease SusceptibilityDNA-Binding ProteinsGene ExpressionGene Knockdown TechniquesHeterograftsHumansMaleMAP Kinase Kinase KinasesBiomarkersDNA-Binding ProteinsMAP3K8 protein, humanMAP Kinase Kinase KinasesProto-Oncogene ProteinsReceptor, Transforming Growth Factor-beta Type ITGFBR1 protein, humanTransforming Growth Factor betamCRPCMetastasisProstate cancerTGF-β signalZNF507

Identifiers

PMID34537073
PMCPMC8449443
OpenAlexW3199390659

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.